Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 1993

Filing Date
Filed March 7, 1994
Period End
December 31, 1993
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed March 7, 1994. Cited figures are marked; the original filing is the authoritative source.

Important note: the filing provided is Schering-Plough Corporation's (not Merck & Co.'s) Form 10-K for fiscal year 1993, covering its pharmaceutical and health care products business.

The analysis below is based on that document. Please verify the company and ticker before using it for investment decisions. Schering-Plough reported 1993 sales of $4,341.3 milliona, up 7% from $4,055.7 million, driven mainly by CLARITIN, the once-daily antihistamine launched in the U.S. in 1993 (worldwide sales of $295 million), and INTRON A, the alpha interferon, which exceeded $570 million.

Income before the extraordinary item and accounting changes rose 15% to $825.0 millionb, and EPS before those items was $4.23, up 18%, helped by share repurchases. Reported net income was $730.8 million ($3.75 per share), held down by a one-time $94.2 million after-tax charge for adopting SFAS No. 106 (postretirement benefits). The effective tax rate fell to 23.5%.

The main risks are PROVENTIL, whose U.S. sales fell 17% to $353 millionc as generic competition grew and may increase after generic albuterol inhalers are approved in 1994; the expected 1994 decline in INTRON A sales in Japan due to a government-mandated price cut; increasing U.S. and international pricing pressure, including proposed health care reform; and the phase-down of Puerto Rico tax exemptions under the 1993 Omnibus Budget Reconciliation Act. Litigation includes DES-related suits claiming about $750 million in total and about sixty antitrust suits, which management does not expect to be material. Net debt rose to $824.3 million, and the company spent $418.3 million on share repurchases and $339.6 million on dividends.

Key Highlights

  1. Sales rose 7% to $4,341.3 million in 1993, with volume growth of 7% and price increases of 2%, partly offset by a 2% unfavorable foreign exchange effect.
  2. Income before extraordinary item and accounting changes grew 15% to $825.0 million; EPS before those items rose 18% to $4.23.
  3. Reported net income was $730.8 million ($3.75 per share), after a $94.2 million (-$0.48 per share) one-time charge for adopting SFAS No. 106.
  4. Growth was led by CLARITIN (worldwide sales $295 million, U.S. launch in 1993) and INTRON A (sales above $570 million), though INTRON A sales in Japan are expected to decline in 1994 due to a price cut.
  5. R&D spending increased 11% to $577.6 million, or 13.3% of sales; cost of sales fell to 20.9% of sales from 22.2%.
  6. PROVENTIL sales fell 17% to $353 million, and generic albuterol inhalers may enter in late 1994, further pressuring sales and profitability.
  7. Net debt rose to $824.3 million; operating cash flow of $962.1 million funded $418.3 million in share repurchases and $339.6 million in dividends ($1.74 per share, up 16%).

Frequently Asked Questions

  1. How did the company's core growth drivers perform in 1993?

    CLARITIN, a once-daily nonsedating antihistamine, achieved $295 million in worldwide sales after its U.S. launch. INTRON A, the alpha interferon for cancer and antiviral use, passed $570 million, including roughly $300 million from Japan. Sales of EULEXIN, CEDAX, and NITRO-DUR also grew.

  2. What is the biggest near-term risk to revenue and earnings?

    Generic competition to PROVENTIL is the most immediate risk, since FDA bioequivalence standards for generic albuterol metered-dose inhalers may lead to generic entries in late 1994. Lower INTRON A pricing in Japan and continued pressure on U.S. and international drug prices are also key concerns.

  3. Were the 1993 earnings affected by one-time items?

    Yes. Reported net income of $730.8 million includes a one-time after-tax charge of $94.2 million ($0.48 per share) from adopting SFAS No. 106 for postretirement benefits. Excluding this charge, income rose 15% to $825.0 million.

  4. What are the significant legal exposures disclosed?

    Subsidiaries are defendants in about 95 lawsuits involving roughly 140 plaintiffs over synthetic estrogen (DES) use, with claims totaling about $750 million against all defendants. The company is also defending about sixty antitrust suits, mostly class actions, alleging refusals to sell at discounted prices. Management believes neither is likely to have a material adverse effect on financial position or results of operations.

  5. How is the company returning capital and managing its balance sheet?

    The company repurchased $418.3 million of common shares in 1993 and raised its quarterly dividend from $0.39 to $0.45, paying $1.74 per share for the year. Net debt increased to $824.3 million, and the debt-to-capital ratio rose to 44% from 41%. The company holds A-1+/P-1 commercial paper ratings and AA/Aa3 bond ratings.